1. Anti-infection Immunology/Inflammation
  2. Influenza Virus Bacterial Antibiotic COX
  3. Indomethacin

Indomethacin (GMP) is Indomethacin (HY-14397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research.

For research use only. We do not sell to patients.

Indomethacin

Indomethacin Chemical Structure

CAS No. : 53-86-1

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Indomethacin:

Other Forms of Indomethacin:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Indomethacin (GMP) is Indomethacin (HY-14397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research[1][2][3].

Cellular Effect
Cell Line Type Value Description References
2008 IC50
12 μM
Compound: Indomethacin
Inhibition of human MRP1 in human 2008 cells
Inhibition of human MRP1 in human 2008 cells
[PMID: 18707884]
2008 IC50
12.6 μM
Compound: indometacin
Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay
Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay
[PMID: 21354800]
A549 IC50
40.6 μM
Compound: indomethacin
Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis
Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis
[PMID: 22992107]
A549 IC50
> 100 μM
Compound: Indomethacin
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
[PMID: 20583750]
A549 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 32987314]
A549 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
[PMID: 32987314]
A549 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 32987314]
BJ IC50
> 50 μM
Compound: C
Cytotoxicity against human BJ cells after 72 hrs by luminescence assay
Cytotoxicity against human BJ cells after 72 hrs by luminescence assay
[PMID: 20129783]
BV-2 IC50
15.2 μM
Compound: Indomethacin
Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production
Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production
[PMID: 37683361]
BV-2 IC50
19.51 μM
Compound: Indomethacin
Antineuroinflammatory activity in LPS-induced mouse BV-2 cells assessed as inhibition of NO production by griess assay
Antineuroinflammatory activity in LPS-induced mouse BV-2 cells assessed as inhibition of NO production by griess assay
[PMID: 37530709]
BV-2 IC50
34.5 μM
Compound: Indomethacin
Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 10 mins followed by LPS stimulation for 24 hrs by Griess assay
Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 10 mins followed by LPS stimulation for 24 hrs by Griess assay
[PMID: 27120704]
BV-2 IC50
35.7 μM
Compound: indomethacin
Inhibition of LPS-activated nitric oxide production in mouse BV2 cells pre-treated for 60 mins before LPS challenge for 24 hrs by Griess assay
Inhibition of LPS-activated nitric oxide production in mouse BV2 cells pre-treated for 60 mins before LPS challenge for 24 hrs by Griess assay
[PMID: 26348503]
BV-2 IC50
55.44 μM
Compound: Indomethacin
Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production pretreated for 1 hr followed by LPS-stimulation and measured after 18 hrs by 2,3-diaminonaphthalene reagent based fluorescence analysis
Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production pretreated for 1 hr followed by LPS-stimulation and measured after 18 hrs by 2,3-diaminonaphthalene reagent based fluorescence analysis
[PMID: 37683361]
BV-2 IC50
7.1 μM
Compound: Indomethacin
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
[PMID: 24042007]
Bel-7402 IC50
> 100 μM
Compound: Indomethacin
Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay
[PMID: 28301815]
Bel7402/5-FU IC50
> 100 μM
Compound: Indomethacin
Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay
[PMID: 28301815]
CHO IC50
0.018 μM
Compound: Indomethacin
In vitro inhibition of the production of PGE-2 in arachidonic acid stimulated chinese hamster ovary (CHO) cells transfected with human cyclooxygenase-1
In vitro inhibition of the production of PGE-2 in arachidonic acid stimulated chinese hamster ovary (CHO) cells transfected with human cyclooxygenase-1
10.1016/S0960-894X(96)00580-X
CHO IC50
0.018 μM
Compound: Indomethacin
Tested in vitro for the ability to inhibit Prostaglandin G/H synthase 1 in chinese hamster ovary (CHO) cells
Tested in vitro for the ability to inhibit Prostaglandin G/H synthase 1 in chinese hamster ovary (CHO) cells
10.1016/S0960-894X(96)00582-3
CHO IC50
0.018 μM
Compound: Indomethacin
In vitro inhibitory potency against human COX-1 in stably transfected chinese hamster ovary (CHO) cells
In vitro inhibitory potency against human COX-1 in stably transfected chinese hamster ovary (CHO) cells
[PMID: 10576684]
CHO IC50
0.026 μM
Compound: Indomethacin
In vitro inhibition of the production of PGE-2 in arachidonic acid stimulated chinese hamster ovary (CHO) cells transfected with human cyclooxygenase-2
In vitro inhibition of the production of PGE-2 in arachidonic acid stimulated chinese hamster ovary (CHO) cells transfected with human cyclooxygenase-2
10.1016/S0960-894X(96)00580-X
CHO IC50
0.026 μM
Compound: Indomethacin
Tested in vitro for the ability to inhibit Prostaglandin G/H synthase 2 in chinese hamster ovary (CHO) cells
Tested in vitro for the ability to inhibit Prostaglandin G/H synthase 2 in chinese hamster ovary (CHO) cells
10.1016/S0960-894X(96)00582-3
CHO IC50
0.026 μM
Compound: Indomethacin
In vitro inhibitory potency against human COX-2 in stably transfected chinese hamster ovary (CHO) cells
In vitro inhibitory potency against human COX-2 in stably transfected chinese hamster ovary (CHO) cells
[PMID: 10576684]
CHO IC50
0.026 μM
Compound: Indomethacin
Inhibition of PGE-2 production in CHO cells expressing human COX-2.
Inhibition of PGE-2 production in CHO cells expressing human COX-2.
[PMID: 10576685]
CHO IC50
0.026 μM
Compound: Indomethacin
In vitro inhibition of PGE-2 produced by arachidonic acid-stimulated CHO cells stably expressing human Prostaglandin G/H synthase 2
In vitro inhibition of PGE-2 produced by arachidonic acid-stimulated CHO cells stably expressing human Prostaglandin G/H synthase 2
[PMID: 9873621]
CHO IC50
0.039 μM
Compound: Indomethacin
Inhibition of PGE-2 production in arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 1
Inhibition of PGE-2 production in arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 1
10.1016/S0960-894X(96)00501-X
CHO IC50
0.049 μM
Compound: Indomethacin
Inhibition of PGE-2 production by arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 2
Inhibition of PGE-2 production by arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 2
10.1016/S0960-894X(96)00501-X
CHO IC50
25 μM
Compound: 2
Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA
Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA
[PMID: 21873070]
CHO IC50
25 μM
Compound: 5
Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA
Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA
[PMID: 20503989]
CHO IC50
3 μM
Compound: Indomethacin
TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells
TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells
[PMID: 10991954]
COS-7 IC50
> 1000 μM
Compound: Indomethacin
Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
CV-1 EC50
50 μM
Compound: Indomethacin
Activation of GAL4 fused human PPARgamma ligand binding domain transfected in african green monkey CV1 cells by CAT reporter assay
Activation of GAL4 fused human PPARgamma ligand binding domain transfected in african green monkey CV1 cells by CAT reporter assay
[PMID: 16643023]
DU-145 IC50
> 100 μM
Compound: 4; Ind
Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay
[PMID: 36257283]
Erythrocyte IC50
0.086 μg/mL
Compound: Indomethacin
Hemolytic activity in human RBC assessed as membrane mortification by absorbance method
Hemolytic activity in human RBC assessed as membrane mortification by absorbance method
[PMID: 29803359]
Erythrocyte IC50
40.04 μg/mL
Compound: Indomethacin
Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method
Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method
[PMID: 30108827]
Erythrocyte IC50
40 μg/mL
Compound: Indomethacin
Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method
Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method
[PMID: 30108882]
HCT-116 EC50
136.8 μM
Compound: Indomethacin
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability
[PMID: 33569941]
HCT-116 IC50
136.8 μM
Compound: INDO
Antiproliferative activity against human HCT116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human HCT116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 30996776]
HCT-15 IC50
> 1000 μM
Compound: Indomethacin
Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
HEK293 IC50
12 μM
Compound: Indometacin
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
[PMID: 22541068]
HEK293 IC50
140 μM
Compound: Indometacin
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
[PMID: 22541068]
HEK293 IC50
41 μM
Compound: Indometacin
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
[PMID: 22541068]
HEK293 IC50
> 50 μM
Compound: C
Cytotoxicity against HEK293 cells after 72 hrs by luminescence assay
Cytotoxicity against HEK293 cells after 72 hrs by luminescence assay
[PMID: 20129783]
HEK293 IC50
> 500 μM
Compound: indomethacin
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
[PMID: 23241029]
HT-29 EC50
312.6 μM
Compound: Indomethacin
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability
[PMID: 33569941]
HT-29 IC50
1052 μM
Compound: Indomethacin
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
[PMID: 22940705]
HT-29 IC50
312.6 μM
Compound: INDO
Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 30996776]
HT-29 IC50
> 100 μM
Compound: 4; Ind
Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay
[PMID: 36257283]
HeLa EC50
0.14 nM
Compound: 1, IMN
Agonist activity at androgen receptor (unknown origin) expressed in HeLa cells co-expressing PSA-(ARE)4-Luc13 assessed as induction of DHT-induced luciferase activity after 20 mins by luciferase reporter gene assay
Agonist activity at androgen receptor (unknown origin) expressed in HeLa cells co-expressing PSA-(ARE)4-Luc13 assessed as induction of DHT-induced luciferase activity after 20 mins by luciferase reporter gene assay
[PMID: 23432095]
HeLa IC50
50 μM
Compound: Indomethacin
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
[PMID: 20583750]
HeLa IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 32987314]
HeLa IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
[PMID: 32987314]
HeLa IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 32987314]
HepG2 IC50
> 50 μM
Compound: C
Cytotoxicity against human HepG2 cells after 72 hrs by luminescence assay
Cytotoxicity against human HepG2 cells after 72 hrs by luminescence assay
[PMID: 20129783]
J774 IC50
0.002 μM
Compound: Indomethacin
In vitro inhibitory activity against Prostaglandin G/H synthase 1 in murine J774 cells
In vitro inhibitory activity against Prostaglandin G/H synthase 1 in murine J774 cells
[PMID: 15857149]
J774 IC50
0.009 μM
Compound: Indomethacin
In vitro inhibitory activity against Prostaglandin G/H synthase 2 in murine J774 cells
In vitro inhibitory activity against Prostaglandin G/H synthase 2 in murine J774 cells
[PMID: 15857149]
J774 IC50
29.6 μM
Compound: Indomethacin
Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
[PMID: 24268542]
J774 IC50
> 100 μM
Compound: Indomethacin
Cytotoxicity against mouse J774 cells assessed as cell survival after 24 hrs by MTT assay
Cytotoxicity against mouse J774 cells assessed as cell survival after 24 hrs by MTT assay
[PMID: 24268542]
J774.A1 IC50
28.42 μM
Compound: Indomethacin
Antiinflammatory activity in mouse J774A1 cells assessed as reduction of LPS-induced nitric oxide production treated 2 hrs before LPS addition measured after 20 hrs by using Griess reagent
Antiinflammatory activity in mouse J774A1 cells assessed as reduction of LPS-induced nitric oxide production treated 2 hrs before LPS addition measured after 20 hrs by using Griess reagent
[PMID: 23688954]
J774.A1 IC50
28.56 μM
Compound: Indomethacin
Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production treated 2 hrs before LPS challenge measured after 20 hrs
Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production treated 2 hrs before LPS challenge measured after 20 hrs
[PMID: 25140384]
K562 IC50
190 μM
Compound: Indomethacin
Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
L02 IC50
> 100 μM
Compound: Indomethacin
Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay
[PMID: 28301815]
LNCaP EC50
238.4 μM
Compound: Indomethacin
Antiproliferative activity against human LNCaP cells assessed as reduction in cell viability
Antiproliferative activity against human LNCaP cells assessed as reduction in cell viability
[PMID: 33569941]
LNCaP IC50
238.4 μM
Compound: INDO
Antiproliferative activity against human LNCAP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human LNCAP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 30996776]
LNCaP IC50
> 300 μM
Compound: Indomethacin
Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 28057407]
MCF7 IC50
> 100 μM
Compound: 4; Ind
Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
[PMID: 36257283]
MCF7 IC50
> 100 μM
Compound: Indomethacin
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 20583750]
MCF7 IC50
> 1000 μM
Compound: Indomethacin
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
MCF7 IC50
> 50 μM
Compound: 1
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 35468536]
MCF7 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 32987314]
MCF7 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
[PMID: 32987314]
MCF7 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 32987314]
MDA-MB-231 IC50
> 100 μM
Compound: Indomethacin
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
[PMID: 20583750]
MDCK-II IC50
235 μM
Compound: Indomethacin
Inhibition of human MRP2 expressed in dog MDCK2 cells
Inhibition of human MRP2 expressed in dog MDCK2 cells
[PMID: 18707884]
MIA PaCa-2 IC50
> 100 mM
Compound: Indomethacin
Cytotoxicity against human MIAPaCa2 cells
Cytotoxicity against human MIAPaCa2 cells
[PMID: 23061607]
Macrophage IC50
22 μM
Compound: indomethacin
Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method
Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method
[PMID: 8988605]
Mast cell IC50
250 μM
Compound: Indomethacin
Inhibition of compound 48/80-induced histamine release in Wister rat Peritoneal mast cells
Inhibition of compound 48/80-induced histamine release in Wister rat Peritoneal mast cells
[PMID: 20586436]
Mast cell IC50
250 μL
Compound: Indomethecin
Inhibition of compound 48/80-induced histamine release in Wistar rat peritoneal mast cells
Inhibition of compound 48/80-induced histamine release in Wistar rat peritoneal mast cells
[PMID: 15270561]
Mononuclear cell line IC50
0.3 μM
Compound: Indomethacin
Inhibition of human PGE-2 production.
Inhibition of human PGE-2 production.
[PMID: 1995900]
Neutrophil IC50
246.35 μM
Compound: Indometacin
Antiinflammatory activity in human neutrophils assessed as inhibition of respiratory burst
Antiinflammatory activity in human neutrophils assessed as inhibition of respiratory burst
[PMID: 20576329]
Neutrophil IC50
271.212 μM
Compound: Indomethacin
Antiinflammatory activity in human neutrophils assessed as inhibition of opsonized zymosan A-mediated superoxide anions production by WST-1 based respiratory burst assay
Antiinflammatory activity in human neutrophils assessed as inhibition of opsonized zymosan A-mediated superoxide anions production by WST-1 based respiratory burst assay
[PMID: 22437110]
Neutrophil IC50
31.98 μg/mL
Compound: Indomethacin
Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release
Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release
[PMID: 21848266]
Neutrophil IC50
32 μM
Compound: Indomethacin
Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced elastase release
Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced elastase release
[PMID: 21316977]
Neutrophil IC50
38.3 μM
Compound: Indomethacin
Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced superoxide anion generation by spectrophotometry
Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced superoxide anion generation by spectrophotometry
[PMID: 21316977]
Neutrophil IC50
38.32 μg/mL
Compound: Indomethacin
Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation
Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation
[PMID: 21848266]
Neutrophil IC50
757.99 μg/mL
Compound: indomethacin
Antiinflammatory activity in human neutrophils assessed inhibition of superoxide anions production
Antiinflammatory activity in human neutrophils assessed inhibition of superoxide anions production
[PMID: 19006373]
Neutrophil IC50
> 40 μM
Compound: indomethacin
Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release
Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release
[PMID: 17197180]
Neutrophil IC50
> 40 μM
Compound: indomethacin
Antiinflammatory activity in neutrophils assessed as inhibition of oxygen radical generation
Antiinflammatory activity in neutrophils assessed as inhibition of oxygen radical generation
[PMID: 17197180]
PC-3 IC50
> 100 μM
Compound: Indomethacin
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
[PMID: 20583750]
PC-3 IC50
> 1000 μM
Compound: Indomethacin
Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
Peritoneal macrophage IC50
147.5 μM
Compound: Indomethacin
Anti-inflammatory activity against LPS-stimulated mouse peritoneal macrophage assessed as reduction in nitric oxide production
Anti-inflammatory activity against LPS-stimulated mouse peritoneal macrophage assessed as reduction in nitric oxide production
[PMID: 37683361]
Platelet IC50
0.1 μM
Compound: Indomethacin
Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins
Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins
[PMID: 114655]
Platelet IC50
0.14 μM
Compound: indomethacin
Anticoagulant activity assessed as inhibition of arachidonic acid induced rabbit platelet aggregation
Anticoagulant activity assessed as inhibition of arachidonic acid induced rabbit platelet aggregation
[PMID: 17197180]
Platelet IC50
0.21 μM
Compound: Indomethacin
Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method
Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method
[PMID: 8988600]
Platelet IC50
1.62 μM
Compound: Indomethacin
Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method
Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method
[PMID: 23639653]
Platelet IC50
2.8 μM
Compound: Indomethacin
Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins
Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins
[PMID: 114655]
Platelet IC50
3.2 μM
Compound: Indomethacin
Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins
Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins
[PMID: 114655]
Platelet IC50
> 100 μM
Compound: indomethacin
Anticoagulant activity assessed as inhibition of thrombin induced rabbit platelet aggregation
Anticoagulant activity assessed as inhibition of thrombin induced rabbit platelet aggregation
[PMID: 17197180]
RAW IC50
15.37 μM
Compound: indomethacin
Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW 264.7 cells after 24 hrs by ELISA
Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW 264.7 cells after 24 hrs by ELISA
[PMID: 21381754]
RAW IC50
23.47 μM
Compound: indomethacin
Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells treated 2 hrs before LPS challenge measured after 18 hrs by Griess reaction method
Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells treated 2 hrs before LPS challenge measured after 18 hrs by Griess reaction method
[PMID: 21381754]
RAW IC50
48.89 μM
Compound: indomethacin
Inhibition of iNOS in LPS-stimulated mouse RAW 264.7 cells after 2 hrs by fluorescence plate reader analysis
Inhibition of iNOS in LPS-stimulated mouse RAW 264.7 cells after 2 hrs by fluorescence plate reader analysis
[PMID: 21381754]
RAW264.7 CC50
> 200 μM
Compound: Indomethacin
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 27575472]
RAW264.7 CC50
> 50 μM
Compound: Indomethacin
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay
[PMID: 31365251]
RAW264.7 CC50
> 50 μM
Compound: Indomethacin
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 2 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 2 hrs by MTT assay
[PMID: 38394380]
RAW264.7 IC50
0.62 μM
Compound: Ind
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production preincubated for 3 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production preincubated for 3 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay
[PMID: 36888988]
RAW264.7 IC50
1.25 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
[PMID: 24806310]
RAW264.7 IC50
1.25 μM
Compound: Indomethacin
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production
[PMID: 25442320]
RAW264.7 IC50
10.7 μM
Compound: Indo
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in absence of LPS by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in absence of LPS by MTT assay
[PMID: 25881822]
RAW264.7 IC50
10.99 μM
Compound: Indometacin
Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Greiss reagent based assay
Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Greiss reagent based assay
[PMID: 34352712]
RAW264.7 IC50
11.6 μM
Compound: Indomethacin
Inhibition of LPS-induced NO production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay
Inhibition of LPS-induced NO production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay
[PMID: 27276091]
RAW264.7 IC50
12.1 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
[PMID: 23755850]
RAW264.7 IC50
12.5 μM
Compound: Indomethacin
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay
[PMID: 26702644]
RAW264.7 IC50
12.96 μM
Compound: Indomethacin
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess reaction based spectrophotometry
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess reaction based spectrophotometry
[PMID: 21807513]
RAW264.7 IC50
12.96 μM
Compound: indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by MTT assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by MTT assay
[PMID: 20879743]
RAW264.7 IC50
13.2 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production after 24 hrs in presence of LPS by colorimetric analysis
Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production after 24 hrs in presence of LPS by colorimetric analysis
[PMID: 27865705]
RAW264.7 IC50
14.1 μM
Compound: indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 1 day by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 1 day by Griess assay
[PMID: 25821895]
RAW264.7 IC50
148 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
[PMID: 23566521]
RAW264.7 IC50
15.8 μM
Compound: Indomethacin
Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay
Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay
[PMID: 24963714]
RAW264.7 IC50
16.5 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reagent based assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reagent based assay
[PMID: 27575472]
RAW264.7 IC50
16.67 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
[PMID: 24660966]
RAW264.7 IC50
16.67 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
[PMID: 26615888]
RAW264.7 IC50
16.7 μM
Compound: Indomethacin
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based assay
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based assay
[PMID: 33533247]
RAW264.7 IC50
17.64 μM
Compound: Indomethacin
Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production by ELISA analysis
Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production by ELISA analysis
[PMID: 37683361]
RAW264.7 IC50
18.7 μM
Compound: Indomethacin
Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA
Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA
[PMID: 24963714]
RAW264.7 IC50
20 μM
Compound: Indo
Inhibition of iNOS in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production for 2 hrs by DAF-FMDA dye based fluorometric assay
Inhibition of iNOS in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production for 2 hrs by DAF-FMDA dye based fluorometric assay
[PMID: 22633833]
RAW264.7 IC50
21.1 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS stimulation measured after 24 hrs by griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS stimulation measured after 24 hrs by griess assay
[PMID: 29261312]
RAW264.7 IC50
24 μM
Compound: Indomethacin
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation measured after 48 hrs by MTT assay
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation measured after 48 hrs by MTT assay
[PMID: 33160760]
RAW264.7 IC50
24 μM
Compound: Indomethacin
Antiinflammatory activity in LPS induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 2 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay
Antiinflammatory activity in LPS induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 2 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay
[PMID: 38394380]
RAW264.7 IC50
26.2 μg/mL
Compound: Indomethacin
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of IFN-gamma and LPS-induced COX2 production preincubated for 2 hrs followed by IFN-gamma and LPS stimulation and measured after 16 hrs by spectrophotometric analysis
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of IFN-gamma and LPS-induced COX2 production preincubated for 2 hrs followed by IFN-gamma and LPS stimulation and measured after 16 hrs by spectrophotometric analysis
[PMID: 33422907]
RAW264.7 IC50
26.3 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production
[PMID: 33422907]
RAW264.7 IC50
3.9 μM
Compound: indomethacin
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma plus LPS-induced NO production
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma plus LPS-induced NO production
[PMID: 24960143]
RAW264.7 IC50
32.2 μM
Compound: Indomethacin
Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent-based assay
Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent-based assay
[PMID: 32247751]
RAW264.7 IC50
32.3 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production for 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production for 24 hrs by Griess assay
[PMID: 33422907]
RAW264.7 IC50
33.6 μM
Compound: Indomethacin
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay
[PMID: 28960979]
RAW264.7 IC50
33.6 μM
Compound: Indomethacin
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess reagent based assay
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess reagent based assay
[PMID: 30024153]
RAW264.7 IC50
34.28 μM
Compound: Indomethacin
Inhibition of LPS induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent based assay
Inhibition of LPS induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent based assay
[PMID: 35660249]
RAW264.7 IC50
34.49 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 1 hrs followed by LPS-stimulation and measured after 24 hrs by griess reagent based assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 1 hrs followed by LPS-stimulation and measured after 24 hrs by griess reagent based assay
[PMID: 36450214]
RAW264.7 IC50
37.5 μM
Compound: Indomethacin
Inhibition of NO production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs by absorbance based assay
Inhibition of NO production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs by absorbance based assay
[PMID: 39110498]
RAW264.7 IC50
38 μM
Compound: Indomethacin
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs coincubated with LPS by Griess reagent based assay
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs coincubated with LPS by Griess reagent based assay
[PMID: 31365251]
RAW264.7 IC50
4.5 μM
Compound: Indo
Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells using L-Arginine substrate incubated for 2 hrs by fluorescence spectrometry
Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells using L-Arginine substrate incubated for 2 hrs by fluorescence spectrometry
[PMID: 25881822]
RAW264.7 IC50
40.3 μM
Compound: Indo
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 2 hrs before LPS challenge measured 18 hrs post LPS challenge by Griess method
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 2 hrs before LPS challenge measured 18 hrs post LPS challenge by Griess method
[PMID: 25555141]
RAW264.7 IC50
40.7 μM
Compound: INDO
Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation for 20 hrs by Griess reagent based assay
Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation for 20 hrs by Griess reagent based assay
[PMID: 35175765]
RAW264.7 IC50
41 μM
Compound: Indomethacin
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs
[PMID: 30920218]
RAW264.7 IC50
42.2 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 20 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 20 hrs by Griess assay
[PMID: 26710212]
RAW264.7 IC50
42.3 μM
Compound: Indometacin
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation and measured after 36 hrs by Griess reagent based assay
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation and measured after 36 hrs by Griess reagent based assay
[PMID: 35512012]
RAW264.7 IC50
42.6 μM
Compound: Indomethacin
Anti-inflammatory activity in mouse RAW264.7 cells assessed as LPS-stimulated inhibition of nitric oxide production incubated simultaneously with LPS for 24 hrs by Griess reagent based assay
Anti-inflammatory activity in mouse RAW264.7 cells assessed as LPS-stimulated inhibition of nitric oxide production incubated simultaneously with LPS for 24 hrs by Griess reagent based assay
[PMID: 26024020]
RAW264.7 IC50
42.6 μM
Compound: indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
[PMID: 25945867]
RAW264.7 IC50
45.51 μM
Compound: Indo
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent method
[PMID: 19931461]
RAW264.7 IC50
45.57 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent-based assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent-based assay
[PMID: 30925056]
RAW264.7 IC50
46.5 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method
[PMID: 28561586]
RAW264.7 IC50
52.8 nM
Compound: Indomethacin
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method
[PMID: 19467877]
RAW264.7 IC50
56.8 μM
Compound: Indo
Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs incubation by Griess analysis
Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs incubation by Griess analysis
[PMID: 37224762]
RAW264.7 IC50
6.3 μM
Compound: indomethacin
Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production after 24 hrs
Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production after 24 hrs
[PMID: 25621853]
RAW264.7 IC50
62.9 μM
Compound: Indomethacin
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay
[PMID: 31403786]
RAW264.7 IC50
7.31 μM
Compound: IND
Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS stimulation and measured after 23 hrs by Griess method
Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS stimulation and measured after 23 hrs by Griess method
[PMID: 39140047]
RAW264.7 IC50
8.5 μM
Compound: Indomethacin
Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 24 hrs by Griess reagent based assay
Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 24 hrs by Griess reagent based assay
[PMID: 37683361]
RAW264.7 IC50
8.8 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs followed by LPS challenge and measured after 12 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs followed by LPS challenge and measured after 12 hrs by Griess assay
[PMID: 31573805]
RAW264.7 IC50
8.8 μM
Compound: Indomethacin
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 18 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 18 hrs by Griess assay
[PMID: 32520548]
RAW264.7 IC50
9.2 μM
Compound: Indo
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in presence of LPS by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in presence of LPS by MTT assay
[PMID: 25881822]
RAW264.7 IC50
> 10 μM
Compound: Ind
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent-based assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent-based assay
[PMID: 32823004]
RAW264.7 IC50
> 100 μM
Compound: indomethacin
Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay
Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay
[PMID: 21381754]
RAW264.7 IC50
> 100 μM
Compound: indomethacin
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay
[PMID: 21381754]
RAW264.7 IC50
> 40 μM
Compound: Ind
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of LPS by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of LPS by MTT assay
[PMID: 32823004]
RAW264.7 IC50
> 40 μM
Compound: Ind
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of LPS by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of LPS by MTT assay
[PMID: 32823004]
RAW264.7 IC50
> 50 μM
Compound: Indomethacin
Cytotoxicity against mouse RAW264.7 cells by MTT assay
Cytotoxicity against mouse RAW264.7 cells by MTT assay
[PMID: 30920218]
RAW264.7 IC50
> 50 μM
Compound: Indomethacin
Cytotoxicity against LPS-induced mouse RAW264.7 cells assessed as reduction in cell viability
Cytotoxicity against LPS-induced mouse RAW264.7 cells assessed as reduction in cell viability
[PMID: 30925056]
RAW264.7 IC50
> 50 μM
Compound: Indomethacin
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability
[PMID: 30925056]
RAW264.7 IC50
> 80 μM
Compound: Indo
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the absence of LPS
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the absence of LPS
[PMID: 22633833]
RAW264.7 IC50
> 80 μM
Compound: Indo
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the presence of LPS
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the presence of LPS
[PMID: 22633833]
RAW264.7 IC50
> 80 μM
Compound: Indo
Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay
Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay
[PMID: 25555141]
RAW264.7 IC50
> 80 μM
Compound: Indo
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay
[PMID: 25555141]
RBL-1 IC50
0.0037 M
Compound: Indomethacin
In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined
In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined
[PMID: 8254620]
RBL-1 IC50
0.5 μM
Compound: 6
Inhibition of Prostaglandin G/H synthase in intact RBL-1 cell line
Inhibition of Prostaglandin G/H synthase in intact RBL-1 cell line
[PMID: 2115586]
RBL-1 IC50
0.5 μM
Compound: Ia
Tested for inhibition of cyclooxygenase (ARBC) in calcium-stimulated rat basophilic leukemia cells(RBL-1)
Tested for inhibition of cyclooxygenase (ARBC) in calcium-stimulated rat basophilic leukemia cells(RBL-1)
10.1016/S0960-894X(00)80450-3
RBL-1 IC50
0.5 μM
Compound: Indomethacin
Compound was evaluated for its inhibitory activity against CO(cyclooxygenase) in intact RBL-1 cell line assay
Compound was evaluated for its inhibitory activity against CO(cyclooxygenase) in intact RBL-1 cell line assay
10.1016/S0960-894X(00)80396-0
RBL-1 IC50
> 100 μM
Compound: 6
Inhibition of 5-lipoxygenase in intact RBL-1 cell line
Inhibition of 5-lipoxygenase in intact RBL-1 cell line
[PMID: 2115586]
RBL-1 IC50
> 100 μM
Compound: Ia
Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1)
Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1)
10.1016/S0960-894X(00)80450-3
RBL-1 IC50
> 100 μM
Compound: Indomethacin
Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay
Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay
10.1016/S0960-894X(00)80396-0
RBL-1 IC50
> 25 μM
Compound: Indomethacin
Inhibitory activity against 5-lipoxygenase of RBL-1 cell line
Inhibitory activity against 5-lipoxygenase of RBL-1 cell line
[PMID: 1507204]
RBL-1 IC50
>> 20 μM
Compound: indomethacin
Inhibition of 5-lipoxygenase in rat RBL-1 cells
Inhibition of 5-lipoxygenase in rat RBL-1 cells
[PMID: 2319562]
Raji IC50
> 50 μM
Compound: C
Cytotoxicity against human Raji cells after 72 hrs by luminescence assay
Cytotoxicity against human Raji cells after 72 hrs by luminescence assay
[PMID: 20129783]
SK-LU-1 IC50
> 1000 μM
Compound: Indomethacin
Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
SW480 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 32987314]
SW480 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
[PMID: 32987314]
SW480 IC50
> 50 μM
Compound: Indometacin
Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay
[PMID: 32987314]
Sf21 IC50
35.2 μM
Compound: Indometacin
Inhibition of human recombinant COX2 expressed in baculovirus infected SF21 cell
Inhibition of human recombinant COX2 expressed in baculovirus infected SF21 cell
[PMID: 20974503]
Sf9 IC50
0.75 μM
Compound: 1, Indomethacin
Inhibition of human COX2 expressed in SF-9 insect cells assessed as conversion of [14C]-arachidonic acid to [14C]-prostaglandins preincubated for 20 mins by thin-layer chromatography analysis
Inhibition of human COX2 expressed in SF-9 insect cells assessed as conversion of [14C]-arachidonic acid to [14C]-prostaglandins preincubated for 20 mins by thin-layer chromatography analysis
[PMID: 21524587]
Sf9 IC50
12.4 μM
Compound: 1
Inhibitory concentration against human recombinant Prostaglandin G/H synthase 1 cloned and expressed in baculovirus (Sf9)
Inhibitory concentration against human recombinant Prostaglandin G/H synthase 1 cloned and expressed in baculovirus (Sf9)
[PMID: 11392547]
Sf9 IC50
30 nM
Compound: 1
Inhibitory concentration against human recombinant Prostaglandin G/H synthase 2 cloned and expressed in baculovirus (Sf9)
Inhibitory concentration against human recombinant Prostaglandin G/H synthase 2 cloned and expressed in baculovirus (Sf9)
[PMID: 11392547]
Sf9 IC50
7.81 μM
Compound: Indomethacin
In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus
In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus
[PMID: 15026050]
TERT-RPE1 IC50
> 40 μM
Compound: 1
Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 35468536]
THP-1 IC50
0.0036 μM
Compound: indomethacin
Effect on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4
Effect on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4
[PMID: 10737736]
THP-1 IC50
19.37 μM
Compound: Indomethacin
Anti-inflammatory activity in human THP-1 cells assessed as inhibition of LPS-stimulated NO production by ELISA analysis
Anti-inflammatory activity in human THP-1 cells assessed as inhibition of LPS-stimulated NO production by ELISA analysis
[PMID: 37683361]
THP-1 IC50
3.6 nM
Compound: Indomethacin
Concentration required to inhibit production of PGE-2 from THP-1 cells stimulated with A-23187
Concentration required to inhibit production of PGE-2 from THP-1 cells stimulated with A-23187
[PMID: 11229777]
THP-1 IC50
> 10 μM
Compound: indomethacin
Effect of pyrrolidine derivatives on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4
Effect of pyrrolidine derivatives on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4
[PMID: 10737736]
THP-1 IC50
> 10 μM
Compound: indomethacin
Inhibition of arachidonic acid production from THP-1 cells stimulated with A-23187 using cellular assay
Inhibition of arachidonic acid production from THP-1 cells stimulated with A-23187 using cellular assay
[PMID: 10737736]
THP-1 IC50
> 100 μM
Compound: Indomethacin
In vitro effect on production of lipopolysaccharide (LPS) -induced IL1-beta in human THP-1 cells
In vitro effect on production of lipopolysaccharide (LPS) -induced IL1-beta in human THP-1 cells
[PMID: 10821716]
THP-1 IC50
> 10000 nM
Compound: Indomethacin
Concentration required to inhibit production of LTC4 from THP-1 cells stimulated with A-23187
Concentration required to inhibit production of LTC4 from THP-1 cells stimulated with A-23187
[PMID: 11229777]
THP-1 IC50
> 10000 nM
Compound: Indomethacin
Concentration required to inhibit production of arachidonic acid from THP-1 cells stimulated with A-23187
Concentration required to inhibit production of arachidonic acid from THP-1 cells stimulated with A-23187
[PMID: 11229777]
U-251 IC50
20.45 μM
Compound: Indomethacin
Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
U-937 IC50
0.002 μM
Compound: 1 Indomethacin
In vitro inhibitory activity against human Prostaglandin G/H synthase 1 (COX-1) in U-937 cells
In vitro inhibitory activity against human Prostaglandin G/H synthase 1 (COX-1) in U-937 cells
[PMID: 12877584]
U-937 IC50
0.003 μM
Compound: 1
Inhibition of Prostaglandin G/H synthase 1 in U-937 cells from human histiocytic lymphoma
Inhibition of Prostaglandin G/H synthase 1 in U-937 cells from human histiocytic lymphoma
[PMID: 11462976]
U-937 IC50
0.02 μM
Compound: Indomethacin
Inhibition of COX-1 in U-937 (human lymphoma) cell microsomes.
Inhibition of COX-1 in U-937 (human lymphoma) cell microsomes.
[PMID: 10576685]
U-937 IC50
0.02 μM
Compound: Indomethacin
Inhibition of Prostaglandin G/H synthase 1 was measured by the inhibition of PGE-2 produced by microsomes from U937 cells incubated in low concentration of arachidonic acid
Inhibition of Prostaglandin G/H synthase 1 was measured by the inhibition of PGE-2 produced by microsomes from U937 cells incubated in low concentration of arachidonic acid
[PMID: 9873621]
VCaP IC50
136.9 μM
Compound: INDO
Antiproliferative activity against human VCaP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human VCaP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
[PMID: 30996776]
Vero C1008 CC50
> 100 μM
Compound: 1; INM
Cytotoxicity against African green monkey Vero E6 cells infected with SARS-CoV-2 assessed as reduction of cell viability measured after 48 hrs by MTT assay
Cytotoxicity against African green monkey Vero E6 cells infected with SARS-CoV-2 assessed as reduction of cell viability measured after 48 hrs by MTT assay
[PMID: 34534839]
Vero C1008 CC50
> 500 μM
Compound: 1; INM
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay
[PMID: 34534839]
In Vitro

Indomethacin (Indometacin) (0-150 μM; 24 h; 3LL-D122 cells) has anticancer activity in vitro[2].
Indomethacin (Indometacin) (0-1000 μM) protects the host cells from damage caused by the virus through activates PKR, resulting in elF2α phosphorylation, and in turn shutting of translation of viral protein and inhibiting replication of the virus (IC50=2μM)[3].
Indomethacin (8 μM, 26 h) induces M1 to M2 macrophage reprogramming in RAW 264.7 cells[4].
Indomethacin (200 μM, 5 d) induces the trans-differentiation of human adipose-derived stem cells into neurogenic cells[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Indomethacin can be used in animal modeling to construct gastrointestinal ulcer models.

Indomethacin (Indometacin) (0.01-10 mg/kg; p.o.; for 3 hours; male Sprague-Dawley rats) induces paw oedema and hyperalgesmeasurement dose-dependently reversed carrageenan-induced hyperalgesia[1].
Indomethacin (Indometacin) (10 mg/mL; p.o.; daily, for 29 days; male C57BL/6J mice) inhibits tumor growth in vivo[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

357.79

Formula

C19H16ClNO4

CAS No.
SMILES

COC1=CC=C(N(C(C2=CC=C(Cl)C=C2)=O)C(C)=C3CC(O)=O)C3=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Indomethacin
Cat. No.:
HY-14397G
Quantity:
MCE Japan Authorized Agent: